Table 2 Association between biological therapy and risk of NMSC in subgroup meta-analyses
Subgroup | No. of studies | RR(95% CI) | I2 value (%) | P value |
|---|---|---|---|---|
All studies | 12 | 1.25 (1.14,1.37) | 37.8 | 0.022 |
Type of NMSC | Â | Â | Â | Â |
Squamous cell skin cancer | 4 | 1.34 (1.10,1.63) | 44.2 | 0.096 |
Basal cell skin cancer | 3 | 1.16 (1.02,1.32) | 0.0 | 0.893 |
Type of biologic therapy | ||||
 TNFI | 10 | 1.23 (1.10,1.37) | 45.2 | 0.017 |
 Abatacept | 3 | 2.00 (1.27,3.15) | 0.0 | 0.689 |
 Rituximab | 2 | 1.02 (0.67,1.56) | 0.0 | 0.754 |
Treatment years | ||||
 Less than 2 years | 2 | 1.04 (0.79,1.37) | 0.0 | 0.633 |
 More than 2 years | 6 | 1.26 (1.17,1.37) | 19.9 | 0.248 |
Study quality | ||||
 NOS score = 7 | 3 | 1.16 (1.00,1.35) | 0.4 | 0.426 |
 NOS score = 8 | 9 | 1.29 (1.15,1.44) | 42.8 | 0.028 |
Sample size | ||||
 < 10,000 | 12 | 1.26 (1.12,1.42) | 45.0 | 0.009 |
 ≥ 10,000 | 4 | 1.21 (1.07,1.36) | 0.0 | 0.667 |